Akers Biosciences, Inc. Distribution Agreements (6326A)
September 30 2015 - 02:02AM
UK Regulatory
TIDMAKR
RNS Number : 6326A
Akers Biosciences, Inc.
30 September 2015
Akers Biosciences, Inc.
Akers Biosciences Signs Distribution Deals in India, Germany,
Italy & Scandinavia
Test for Heparin Induced Thrombocytopenia Now Represented in 30
Countries
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a medical device company focused on
reducing the cost of healthcare through faster, easier diagnostics,
has signed distribution agreements to market its flagship test for
heparin--induced thrombocytopenia ("HIT") in India, Germany, Italy
and Scandinavia. The Company's HIT test, based on Akers Bio's
proprietary PIFA technology, is now represented in thirty countries
worldwide. Akers Bio now has distribution in every major diagnostic
market in the world.
Akers has developed the only U.S. and E.U. cleared rapid test to
detect a potentially fatal allergy to the widely used blood
thinner, heparin. This clinical syndrome known as HIT reverses
heparin's intended therapeutic effect and transforms it into a
clotting agent. Patients suffering HIT are at risk of developing
limb- and life-threatening complications, so the rapid diagnosis
provided by the Company's Heparin/PF4 devices is paramount to
effective, clinical decision making. Millions of patients are
exposed to heparin around the world each year and between 1% and 5%
of those patients receive a HIT diagnosis. The largest at-risk
populations are patients undergoing major cardiac or orthopedic
surgical procedures.
The Company's diagnostic test is not only a valuable tool for
HIT diagnosis but also for rapidly ruling out HIT, thus avoiding
the need to administer expensive direct thrombin inhibitors in the
many cases where HIT is suspected but ultimately not present. While
the number of cases differs from country to country, the value
proposition of reducing hospital costs is applicable regardless of
geography.
"While the U.S. continues to be our main market for the HIT
test, other countries where heparin is widely used are beginning to
recognize the medical and economic benefits of being able to
diagnose - or rule-out - the presence of HIT rapidly," said Raymond
F. Akers, Jr. PhD, Co-founder and Executive Chairman. "India,
Germany, Italy and Scandinavia are all big potential markets for
this test as heparin is the primary anticoagulant used in surgeries
in each of them," continued Dr. Akers.
"In just a year Akers Bio has moved from having practically no
representation for this product outside of the U.S. to having a
network of distributors targeting 29 ex-U.S. markets," continued
Dr. Akers.
"We are delighted to welcome our new distribution partners in
India, Germany, Italy and Scandinavia and look forward to
supporting their efforts to generate sales in their respective
regions," added Nicolas Daurel, Vice President, Sales and Marketing
for EMEA.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLMMTMBTTTMA
(END) Dow Jones Newswires
September 30, 2015 02:02 ET (06:02 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2023 to Mar 2024